All News
Baricitinib Effective in JIA Subsets
A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo.
Read Article
GCA and the Risk of Cerebrovascular Ischemic Events
Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital.
Read Article
Upadacitinib Outcomes in High Risk RA Patients
A safety analysis of six phase III SELECT trials showed that higher-risk rheumatoid arthritis (RA) patients had an increased risk of MACE, malignancy (excluding NMSC) and venous thromboembolic events (VTE) regardless of being treated with either upadacitinib (UPA) or adalimumab (ADA).
Read Article
Pain is the leading cause of disability worldwide. Chronic pain affects 33-50% of the population. High impact chronic pain is seen in 4.8% of US adult population. Chronic pain accounts for 22-50% of GP consultations. More from BMJ.. https://t.co/IRVpJZNS0L https://t.co/YVIM38aWWK
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review of "Treatments for Lupus Nephritis" from Isenberg et al - discussing:
- Pathogenesis, outcomes
- Conventional Rx
- B cell targeting: BEL, RTX, Obintuzumab, Atacicept & more
- Sequential Rx: Synviose, BEAT, BLISS-Believe
- JAKi & more https://t.co/X0xn9FeL0j https://t.co/Fiyf5Drh93
Links:
Dr. John Cush RheumNow ( View Tweet)
Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform.
https://t.co/CeLTCbB2nO https://t.co/qYXt8gCHjd
Links:
Dr. John Cush RheumNow ( View Tweet)
NIH MOST study 2093 OA pts w/ Knee Xrays/CT/Pain scores q8 mos x2 yrs. IA mineralization seen in 10% knees & assoc w/ a 2 fold higher risk of freq knee pain & OR 1.86 of freq intermit/constant pain. IA mineralz. meniscus or Jt capsule=higher odds of pain https://t.co/CacJ40DVyL https://t.co/Zhwv98d6Pe
Links:
Dr. John Cush RheumNow ( View Tweet)
Since the end of COVID, how often do you see Pharma Sales Reps (PSRs)?
Dr. John Cush RheumNow ( View Tweet)
Scleroderma – Thick and Thin
This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.
https://t.co/IF5c8MF1zk https://t.co/zhwR4SofHt
Links:
Dr. John Cush RheumNow ( View Tweet)
In Memoriam: Dr. K. Frank Austen (1928-2023)
Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95.
https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R
Links:
Dr. John Cush RheumNow ( View Tweet)
Scary Outcomes with Systemic Sclerosis Sine Scleroderma
The hallmark of SSc is scleroderma, but less than 10% of SSc patients have ssSSc. A EUSTAR database review compared the manifestations and outcomes of ssSSC to lcSSc and dcSSc.
https://t.co/WwwmDxt5DL https://t.co/iXepaWvoCY
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioids Ineffective in Acute Lower Back and Neck Pain
A randomised controlled trial including 347 participants with lower back or neck pain found there was no benefit of taking opioid pain relievers compared to placebo.
https://t.co/96mETyhKyL https://t.co/48ojNCnoZW
Links:
Dr. John Cush RheumNow ( View Tweet)
Remembering Dr. Naomi F. Rothfield - As one of UConn School of Medicine’s first women faculty, legendary internationally-renowned rheumatologist Dr. had a nearly 50 year career at UConn Health retiring in 2016. She passed away on Sunday, July 2. https://t.co/jUESbCySRR https://t.co/50inpx7xRW
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
Links:
Dr. John Cush RheumNow ( View Tweet)
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/uKArtikNMu
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew : Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK https://t.co/RuPZ0ys0xW
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @bella_mehta : An interesting biomarker in #sJIA- helps differentiate it from other diseases, including infections and other inflammatory diseases! - kids with fever! serum calprotectin (MRP8/14) particle enhanced immuno-turbidimeteic assay (sCAL Turbi). 650 pts #EULAR2023
Dr. John Cush RheumNow ( View Tweet)
RT @Janetbirdope : What would you do? A middle aged woman has pain and impaired hand function with her PIP&DIP erosive hand #osteoarthritis? Exam - jts are tender w soft tissue swelling? #NSAIDs, #denosumab, #methotrexate? 🤷♀️ A +RCT of #MTX in #erosive #hand #OA at #EULAR2023
Dr. John Cush RheumNow ( View Tweet)
RT @Yuz6Yusof : #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favored DAZ Group. Phase 3 RCTs are underway
Dr. John Cush RheumNow ( View Tweet)
Long-Term Efficacy and Safety of a JAKi in RA
How might long-term efficacy and safety data from a study of a JAKi in TNFi-IR patients with RA influence clinical decision making? Watch Dr. Stan Cohen discuss.
Sponsored by AbbVie US Medical Affairs
https://t.co/mvVtlMJTc2 https://t.co/YJX3nymDuU
Links:
Dr. John Cush RheumNow ( View Tweet)